A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Stopped early · Phase 3

Conditions studied: Iron Deficiency Anemia

In brief

Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.

Key facts

Study ID

NCT01264679

Run by

AMAG Pharmaceuticals, Inc.

People needed

8

Starts

2011-12-27

Expected to finish

2015-04-24

Last updated by the study team

2022-04-28

Who can join

Age: 1 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• AMAG Pharmaceuticals, Inc. — Waltham, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.